Open Access
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
M. Gordon Joyce
1, 2
,
Wei-Hung Chen
1, 3
,
Rajeshwer S. Sankhala
1, 3
,
Agnes Hajduczki
1, 3
,
Paul Thomas
1, 3
,
Misook Choe
1, 3
,
Elizabeth J. Martinez
1, 3
,
William C Chang
1, 3
,
Caroline E. Peterson
1, 3
,
Elaine B Morrison
4
,
Clayton S. Smith
5, 6
,
Rita P.-Y. Chen
7, 8, 9, 10
,
Aslaa Ahmed
11
,
Lindsay Wieczorek
4, 12
,
A S Anderson
13, 14
,
James Brett Case
7, 8, 9, 10
,
李艺凡 Li Yifan
4, 12
,
Therese Oertel
13, 14
,
Lorean Rosado
4, 12
,
Akshaya Ganesh
13, 14
,
Connor Whalen
13, 14
,
Joshua M Carmen
4
,
Letzibeth Mendez Rivera
4, 12
,
Christopher P Karch
4, 12
,
Neelakshi Gohain
4, 12
,
Zuzana Villar
4, 12
,
David McCurdy
4, 12
,
Zoltan Beck
4, 12
,
Jiae Kim
4, 12
,
Shikha Shrivastava
4, 12
,
Ousman Jobe
4, 12
,
Vincent Dussupt
4, 12
,
Sebastian Molnar
4, 12
,
Ursula Tran
4, 12
,
Chandrika B Kannadka
4, 12
,
Sandrine Soman
11
,
Caitlin Kuklis
11
,
Michelle Zemil
4, 12
,
Htet Khanh
5, 6
,
Wei-Min Wu
5, 6
,
Matthew Cole
15
,
Debra K. Duso
15
,
Larry W. Kummer
15
,
Tricia J Lang
15
,
Shania E Muncil
15
,
Jeffrey R. Currier
11
,
Shelly J. Krebs
4, 12
,
Saravanan Rajan
16
,
Patrick M Mctamney
17
,
Mark T Esser
17
,
William Reiley
15
,
Morgane Rolland
4, 12
,
Natalia de Val
5, 6
,
MICHAEL P. DIAMOND
7, 8, 9, 10
,
Gregory D. Gromowski
11
,
Gary R Matyas
4
,
Mangala Rao
4
,
Nelson Michael
18
,
1
Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA
|
2
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. Electronic address: gjoyce@eidresearch.org.
|
3
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
|
4
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
|
11
Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
|
12
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
|
13
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
|
15
Trudeau Institute, Inc., Saranac Lake, NY, USA.
|
16
Antibody Discovery and Protein Engineering (ADPE), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
|
17
Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
|
18
Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
|
19
Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA. Electronic address: kayvon.modjarrad.civ@mail.mil.
|
Publication type: Journal Article
Publication date: 2021-12-08
scimago Q1
wos Q1
SJR: 3.796
CiteScore: 12.9
Impact factor: 6.9
ISSN: 22111247, 26391856
PubMed ID:
34919799
General Biochemistry, Genetics and Molecular Biology
Abstract
Summary
The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2. A spike-ferritin nanoparticle (SpFN) vaccine elicits neutralizing titers (ID50 > 10,000) following a single immunization, whereas RBD-ferritin nanoparticle (RFN) immunogens elicit similar responses after two immunizations and also show durable and potent neutralization against circulating VoCs. Passive transfer of immunoglobulin G (IgG) purified from SpFN- or RFN-immunized mice protects K18-hACE2 transgenic mice from a lethal SARS-CoV-2 challenge. Furthermore, S-domain nanoparticle immunization elicits ACE2-blocking activity and ID50 neutralizing antibody titers >2,000 against SARS-CoV-1, highlighting the broad response elicited by these immunogens.Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Vaccines
13 publications, 8.78%
|
|
|
bioRxiv
7 publications, 4.73%
|
|
|
Nature Communications
6 publications, 4.05%
|
|
|
Viruses
4 publications, 2.7%
|
|
|
Frontiers in Immunology
4 publications, 2.7%
|
|
|
Vaccine
4 publications, 2.7%
|
|
|
npj Vaccines
3 publications, 2.03%
|
|
|
International Journal of Biological Macromolecules
3 publications, 2.03%
|
|
|
Expert Review of Vaccines
3 publications, 2.03%
|
|
|
Cell
3 publications, 2.03%
|
|
|
Science advances
2 publications, 1.35%
|
|
|
Advanced healthcare materials
2 publications, 1.35%
|
|
|
International Journal of Molecular Sciences
2 publications, 1.35%
|
|
|
Signal Transduction and Targeted Therapy
2 publications, 1.35%
|
|
|
Journal of Medical Virology
2 publications, 1.35%
|
|
|
Journal of Virology
2 publications, 1.35%
|
|
|
The Lancet Microbe
2 publications, 1.35%
|
|
|
International Journal of Pharmaceutics
2 publications, 1.35%
|
|
|
iScience
2 publications, 1.35%
|
|
|
Nanoscale
2 publications, 1.35%
|
|
|
Microbial Drug Resistance
1 publication, 0.68%
|
|
|
Frontiers in Bioengineering and Biotechnology
1 publication, 0.68%
|
|
|
Nature Immunology
1 publication, 0.68%
|
|
|
Journal of Biomedical Science
1 publication, 0.68%
|
|
|
Experimental and Molecular Medicine
1 publication, 0.68%
|
|
|
Science China Life Sciences
1 publication, 0.68%
|
|
|
Cell Reports
1 publication, 0.68%
|
|
|
Process Biochemistry
1 publication, 0.68%
|
|
|
Biotechnology Advances
1 publication, 0.68%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
39 publications, 26.35%
|
|
|
Springer Nature
23 publications, 15.54%
|
|
|
MDPI
22 publications, 14.86%
|
|
|
Cold Spring Harbor Laboratory
19 publications, 12.84%
|
|
|
Wiley
9 publications, 6.08%
|
|
|
American Chemical Society (ACS)
9 publications, 6.08%
|
|
|
Frontiers Media S.A.
6 publications, 4.05%
|
|
|
Taylor & Francis
6 publications, 4.05%
|
|
|
Royal Society of Chemistry (RSC)
4 publications, 2.7%
|
|
|
American Association for the Advancement of Science (AAAS)
3 publications, 2.03%
|
|
|
American Society for Microbiology
3 publications, 2.03%
|
|
|
Mary Ann Liebert
2 publications, 1.35%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.68%
|
|
|
The American Association of Immunologists
1 publication, 0.68%
|
|
|
Research Square Platform LLC
1 publication, 0.68%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
148
Total citations:
148
Citations from 2024:
74
(50%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Joyce M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity // Cell Reports. 2021. Vol. 37. No. 12. p. 110143.
GOST all authors (up to 50)
Copy
Joyce M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity // Cell Reports. 2021. Vol. 37. No. 12. p. 110143.
Cite this
RIS
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Joyce,
author = {M. Gordon Joyce and Wei-Hung Chen and Rajeshwer S. Sankhala and Agnes Hajduczki and Paul Thomas and Misook Choe and Elizabeth J. Martinez and William C Chang and Caroline E. Peterson and Elaine B Morrison and Clayton S. Smith and Rita P.-Y. Chen and Aslaa Ahmed and Lindsay Wieczorek and A S Anderson and James Brett Case and 李艺凡 Li Yifan and Therese Oertel and Lorean Rosado and Akshaya Ganesh and Connor Whalen and Joshua M Carmen and Letzibeth Mendez Rivera and Christopher P Karch and Neelakshi Gohain and Zuzana Villar and David McCurdy and Zoltan Beck and Jiae Kim and Shikha Shrivastava and Ousman Jobe and Vincent Dussupt and Sebastian Molnar and Ursula Tran and Chandrika B Kannadka and Sandrine Soman and Caitlin Kuklis and Michelle Zemil and Htet Khanh and Wei-Min Wu and Matthew Cole and Debra K. Duso and Larry W. Kummer and Tricia J Lang and Shania E Muncil and Jeffrey R. Currier and Shelly J. Krebs and Victoria R Polonis and Saravanan Rajan and Patrick M Mctamney and others},
title = {SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity},
journal = {Cell Reports},
year = {2021},
volume = {37},
publisher = {Elsevier},
month = {dec},
url = {https://doi.org/10.1016/j.celrep.2021.110143},
number = {12},
pages = {110143},
doi = {10.1016/j.celrep.2021.110143}
}
Cite this
MLA
Copy
Joyce, M. Gordon, et al. “SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.” Cell Reports, vol. 37, no. 12, Dec. 2021, p. 110143. https://doi.org/10.1016/j.celrep.2021.110143.